Title Host response cytokine signatures in viral and nonviral acute exacerbations of chronic obstructive pulmonary disease.
Author Almansa, Raquel; Sanchez-Garcia, Monica; Herrero, Agueda; Calzada, Sergio; Roig, Vicente; Barbado, Julia; Rico, Lucia; Bobillo, Felipe; Eiros, Jose M; Iglesias, Veronica; de Lejarazu, Raul Ortiz; Bermejo-Martin, Jesus F
Journal J Interferon Cytokine Res Publication Year/Month 2011-May
PMID 21235417 PMCID -N/A-
Affiliation 1.Translational Medicine Program, Infection and Immunity Unit, Microbiology Service, Hospital Clinico Universitario-IECSCYL, Valladolid, Spain.

Viruses are strongly associated with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Interferon-inducible protein-10 has been recently described as a biomarker of human rhinovirus infection, but there are no reports on the role of other immune mediators in AECOPD of viral origin. As an attempt to evaluate the differences in the systemic immune mediators profiles between AECOPD patients with presence/absence of viral infection, we measured 27 cytokines, chemokines, and cellular growth factors in the plasma of 40 patients with AECOPD needing of hospitalization by using a Luminex-based assay. These patients were screened for the presence of 16 different respiratory viruses in pharyngeal swabs. Ten healthy controls were recruited for comparison purposes. Both the group of patients with an associated viral infection (n = 11) and those with no viral infection (n = 29) showed high levels of vascular endothelial growth factor, interleukin-13 (IL-13), and IL-2. On the other hand, viral infection in AECOPD induced a coordinated response of innate immunity chemokines (eotaxin, interferon-inducible protein-10, IL-8), Th1 cytokines (IL-12p70, IL-15), and the immunomodulatory IL-10. This profile corresponds to a typical antiviral response signature previously documented for other viral infections. The identification of early cytokine signatures associated with viral infection in AECOPD could contribute to design better treatment strategies for this disease.

  • Copyright © 2023
    National Institute of Pathogen Biology, CAMS & PUMC, Bejing, China
    All rights reserved.